vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与ROYAL GOLD INC（RGLD）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是ROYAL GOLD INC的1.1倍（$406.6M vs $375.3M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs 24.9%，领先35.5%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 85.3%），过去两年BIOCRYST PHARMACEUTICALS INC的营收复合增速更高（109.4% vs 58.8%）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Royal Gold Inc.是全球领先的贵金属流权与特许权经营企业，收购并管理多元化的矿业项目流权、净熔炼收益特许权及相关权益，资产覆盖黄金、白银、铜等品类，业务遍及多地区，无需直接承担采矿运营风险。
BCRX vs RGLD — 直观对比
营收规模更大
BCRX
是对方的1.1倍
$375.3M
营收增速更快
BCRX
高出123.8%
85.3%
净利率更高
BCRX
高出35.5%
24.9%
两年增速更快
BCRX
近两年复合增速
58.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $375.3M |
| 净利润 | $245.8M | $93.6M |
| 毛利率 | 97.7% | 64.6% |
| 营业利润率 | 64.0% | 56.2% |
| 净利率 | 60.5% | 24.9% |
| 营收同比 | 209.1% | 85.3% |
| 净利润同比 | 1017.5% | -12.8% |
| 每股收益（稀释后） | $1.13 | $1.04 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXRGLD
| Q4 25 | $406.6M | $375.3M | ||
| Q3 25 | $159.4M | $252.1M | ||
| Q2 25 | $163.4M | $209.6M | ||
| Q1 25 | $145.5M | $193.4M | ||
| Q4 24 | $131.5M | $202.6M | ||
| Q3 24 | $117.1M | $193.8M | ||
| Q2 24 | $109.3M | $174.1M | ||
| Q1 24 | $92.8M | $148.9M |
净利润BCRXRGLD
| Q4 25 | $245.8M | $93.6M | ||
| Q3 25 | $12.9M | $126.8M | ||
| Q2 25 | $5.1M | $132.3M | ||
| Q1 25 | $32.0K | $113.5M | ||
| Q4 24 | $-26.8M | $107.4M | ||
| Q3 24 | $-14.0M | $96.2M | ||
| Q2 24 | $-12.7M | $81.2M | ||
| Q1 24 | $-35.4M | $47.2M |
毛利率BCRXRGLD
| Q4 25 | 97.7% | 64.6% | ||
| Q3 25 | 98.6% | 73.6% | ||
| Q2 25 | 98.3% | 72.6% | ||
| Q1 25 | 96.9% | 69.4% | ||
| Q4 24 | 95.4% | 70.3% | ||
| Q3 24 | 97.3% | 66.6% | ||
| Q2 24 | 98.4% | 64.7% | ||
| Q1 24 | 98.6% | 58.4% |
营业利润率BCRXRGLD
| Q4 25 | 64.0% | 56.2% | ||
| Q3 25 | 18.6% | 64.4% | ||
| Q2 25 | 18.2% | 67.7% | ||
| Q1 25 | 14.6% | 63.6% | ||
| Q4 24 | -3.4% | 65.9% | ||
| Q3 24 | 6.6% | 61.3% | ||
| Q2 24 | 8.0% | 58.6% | ||
| Q1 24 | -15.6% | 50.7% |
净利率BCRXRGLD
| Q4 25 | 60.5% | 24.9% | ||
| Q3 25 | 8.1% | 50.3% | ||
| Q2 25 | 3.1% | 63.1% | ||
| Q1 25 | 0.0% | 58.7% | ||
| Q4 24 | -20.4% | 53.0% | ||
| Q3 24 | -12.0% | 49.7% | ||
| Q2 24 | -11.6% | 46.6% | ||
| Q1 24 | -38.1% | 31.7% |
每股收益（稀释后）BCRXRGLD
| Q4 25 | $1.13 | $1.04 | ||
| Q3 25 | $0.06 | $1.92 | ||
| Q2 25 | $0.02 | $2.01 | ||
| Q1 25 | $0.00 | $1.72 | ||
| Q4 24 | $-0.13 | $1.63 | ||
| Q3 24 | $-0.07 | $1.46 | ||
| Q2 24 | $-0.06 | $1.23 | ||
| Q1 24 | $-0.17 | $0.72 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $233.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $7.2B |
| 总资产 | $514.2M | $9.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXRGLD
| Q4 25 | $274.7M | $233.7M | ||
| Q3 25 | $212.9M | $172.8M | ||
| Q2 25 | $260.0M | $248.2M | ||
| Q1 25 | $295.1M | $240.8M | ||
| Q4 24 | $320.9M | $195.5M | ||
| Q3 24 | $96.8M | $127.9M | ||
| Q2 24 | $78.4M | $74.2M | ||
| Q1 24 | $84.3M | $137.9M |
总债务BCRXRGLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $50.0M | ||
| Q1 24 | — | — |
股东权益BCRXRGLD
| Q4 25 | $-119.2M | $7.2B | ||
| Q3 25 | $-387.9M | $3.4B | ||
| Q2 25 | $-421.6M | $3.3B | ||
| Q1 25 | $-451.9M | $3.2B | ||
| Q4 24 | $-475.9M | $3.1B | ||
| Q3 24 | $-468.6M | $3.0B | ||
| Q2 24 | $-475.6M | $3.0B | ||
| Q1 24 | $-476.2M | $2.9B |
总资产BCRXRGLD
| Q4 25 | $514.2M | $9.5B | ||
| Q3 25 | $446.4M | $4.5B | ||
| Q2 25 | $457.2M | $3.6B | ||
| Q1 25 | $480.0M | $3.5B | ||
| Q4 24 | $490.4M | $3.4B | ||
| Q3 24 | $491.3M | $3.3B | ||
| Q2 24 | $472.4M | $3.3B | ||
| Q1 24 | $467.9M | $3.3B |
负债/权益比BCRXRGLD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.02× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $241.7M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | — |
| 自由现金流率自由现金流/营收 | 71.6% | — |
| 资本支出强度资本支出/营收 | 0.2% | — |
| 现金转化率经营现金流/净利润 | 1.19× | 2.58× |
| 过去12个月自由现金流最近4个季度 | $344.9M | — |
8季度趋势，按日历期对齐
经营现金流BCRXRGLD
| Q4 25 | $292.0M | $241.7M | ||
| Q3 25 | $41.6M | $174.0M | ||
| Q2 25 | $41.3M | $152.8M | ||
| Q1 25 | $-27.5M | $136.4M | ||
| Q4 24 | $-5.2M | $141.1M | ||
| Q3 24 | $8.2M | $136.7M | ||
| Q2 24 | $-1.4M | $113.5M | ||
| Q1 24 | $-53.7M | $138.3M |
自由现金流BCRXRGLD
| Q4 25 | $291.2M | — | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-53.9M | — |
自由现金流率BCRXRGLD
| Q4 25 | 71.6% | — | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | -58.1% | — |
资本支出强度BCRXRGLD
| Q4 25 | 0.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.3% | — |
现金转化率BCRXRGLD
| Q4 25 | 1.19× | 2.58× | ||
| Q3 25 | 3.23× | 1.37× | ||
| Q2 25 | 8.12× | 1.15× | ||
| Q1 25 | -859.91× | 1.20× | ||
| Q4 24 | — | 1.31× | ||
| Q3 24 | — | 1.42× | ||
| Q2 24 | — | 1.40× | ||
| Q1 24 | — | 2.93× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
